MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED DECEMBER 31, 2021
Wednesday, April 27, 2022
Our vision is to become a leading pharmaceutical company within the U.S., offering a growing portfolio of products that improve patients' lives.
At Medicure, we are focused on improving the health of patients by offering a growing portfolio of products and services and ensuring all patients get access to care they need.
Medicure Inc. announced full year and fourth quarter 2021 results for the year ended 31 December 2021 on Thursday 28 April.
Medicure Inc.– via Marley Drug, creates a direct-to-consumer e-commerce pharmacy solution. The service is available in all 50 states and can fulfill a formulary of over 100 prescription medications.
Partnership will integrate Marley Drug as the sole mail-order pharmacy for the RxSpark platform allowing consumers using the platform to receive medication directly to their door.
Medicure has filed with the FDA an IND for the use of MC-1 as a novel treatment for seizures associated with pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency.
At Medicure, we are focused on improving the heart health of patients by delivering safe and efficacious cardiovascular medicines and ensuring all patients get access to therapy.
Medicure Announces Early Completion of Enrollment for iSPASM, a Phase 1/2a Exploratory Clinical Trial in Patients with Aneurysmal Subarachnoid Hemorrhage
Copyright © 2022 Medicure Inc. All Rights Reserved. | Privacy Statement